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Abstract
 In this study, we investigated the anti-inflammatory and pain relief effects of a new canine diet supplement con-
taining a mixture of Boswellia serrata Roxb., Curcuma longa, green tea extract, glucosamine, chondroitin sulfate, hyaluronic 
acid, and collagen type II-not hydrolised in dogs with osteoarthritis. A total of 13 dogs with osteoarthritis were enrolled in 
the study. All of them were orally administered with the diet supplement for 60 days. All the animals were subject to veteri-
nary evaluations and owners filled questionnaires on chronic pain (Helsinki chronic pain index). All the patients completed 
the study, no side effects and no changes in the basic metabolism was reported, confirming the safety and tolerability of the 
product. Combining results from the veterinarian and from the owner evaluations, most of the dogs improved their con-
dition. The treatment resulted more effective in severe cases. Several treatment options are currently available for treating 
dogs with osteoarthritis, but there is an increasing interest in the use of diet supplements given their efficacy and safety. Our 
findings suggest that our dietary supplement has beneficial effects in alleviating chronic orthopedic pain and in reducing 
clinical signs in dogs with osteoarthritis.
Keywords: Osteoarthritis; Boswellia; Lameness; Chronic pain; Dietary supplement
Highlights
- Osteoarthritis is a common cause of chronic pain in dogs.
- Diet supplements are valid alternative to alleviate chronic pain.
- Diet supplements are safe and have anti-inflammatory and pain relief effects.
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Introduction
 Osteoarthritis (OA), also known as degenerative joint 
disease, is a condition common in both humans and compan-
ion animals that has been described for over a hundred years 
[1]. As in humans, the pathogenesis of canine OA involves 
changes in all tissues of the synovial joint. OA happens when 
trauma or cellular damage changes the normal homeostasis of 
the joint, releasing inflammatory mediators and degradative 
enzymes. Chronic pain and disability are the result of the de-
terioration of the articular cartilage. The most frequent causes 
of disease in dogs are the excessive exercise, trauma and/or 
genetic predisposition. In dogs aging more than 1 year, OA 
is very common. In addition, breed, gender, animal size and 
weight are common risk factors. The course of OA is very slow; 
common findings are the degeneration of the cartilage, hyper-
trophy of bone at the margins and changes in the synovial 
membrane [2].
 Diagnosing OA in dogs begins with owners observ-
ing the pain and stiffness. The owners usually notice the pain 
while the animal is doing its common activities during the day. 
Pain is a very subjective sensation, therefore, it is very difficult 
to assess. In human medicine, the patient provides informa-
tion on its condition, in case of dogs, other methods must be 
adopted. In the past years, several questionnaires have been 
developed and validated to assess acute and chronic pain in 
animals [3-5]. In particular, the owner has been found to be 
able to identify signs of chronic pain and to highlight changes 
of attitude and behavior of affected dogs over time. For exam-
ple, the Helsinki chronic pain index (HCPI) has been validated 
for chronic pain associated with OA in dogs through the use 
of a multifactorial and descriptive owner questionnaire. The 
HCPI consists of 11 questions on the dog’s mood, lameness, 
and willingness to move, play, and jump [5-7].
 A part from this, veterinary evaluations are valuable 
and objective tools to diagnose OA and to classify the level and 
progress of the disease when setting up a treatment. Radio-
graphic evidence, patient symptoms, type and degree of lame-
ness and OA risk factors can help predicting the risk of joint 
degradation [2]. 
 Unfortunately, once clinically evident, OA cannot be 
cured in both animals and humans. Therefore, being pain the 
dominant symptom, the current goal of any treatment given 
is the management of the chronic pain and associated loss of 
function. In both humans and dogs, the most common ap-
proaches include lifestyle changes (i.e. weight loss, reduced 
exercise, etc.), surgical treatment, or the use of drugs (non-
steroidal anti-inflammatory drugs, NSAIDs; N-methyl-D-as-
partate, NMDA, inhibitors; Opioids; Corticosteroids) [1,8,9]. 
These agents are of variable efficacy but may be associated 
with a significant number of side effects, toxicities, and tol-
erance over time [10]. Accordingly, there has been significant 
inquiries into different approaches to OA. Physiotherapy, acu-
puncture, and hydrotherapy are increasingly used as compli-
mentary therapies [11]. The use of dietary supplements and 
traditional herbal medicinal products in dogs and other com-
panion animals are becoming of great interest in the scientific 
veterinary community although there are limited numbers of 
rigorous randomized controlled trials currently available as 
pointed out by some researchers [12]. Beside this, these dietary 
supplements present the advantage of having few side effects 
but chondroprotective and anti-inflammatory properties as re-
ported in in vivo studies [7,13]. 
 Glucosamine regulates the synthesis of collagen in 
cartilage and may provide mild anti-inflammatory effects, 
while chondroitin sulfate inhibits destructive enzymes in joint 
fluid and cartilage. The two work in a synergic manner [14] in-
creasing their own positive effects on cartilage. They could also 
be found associated with other chondro protectants such as the 
hyaluronic acid or the undenatured type II collagen, being the 
latest able to reduce pain and improve joint mobility and flex-
ibility [15-17]. In addition, natural ingredients like Boswellia 
serrata [13,18], Curcuma longa [18-20] and green tea extract 
[19,21] orally administered singly or in combination, have been 
reported to be safe and to have beneficial effects in the treat-
ment of inflammatory processes in animals and humans. 
In this study, we investigated the anti-inflammatory and pain 
relief effects of a new canine diet supplement containing a mix-
ture of Boswellia serrata Roxb., Curcuma longa and green tea 
extract in addition to some chondro protectants (Glucosamine 
(purity 99%), chondroitin sulfate (low molecular weight, purity 
100%), hyaluronic acid, collagen type II-not hydrolised) on cli-
ent owned dogs with OA reporting chronic pain. 
Materials & Methods
Animals included and recruitment 
 Medium to large-breed client-owned dogs with OA 
were recruited from the Veterinary Clinic VETLAN (Battipa-
glia, Italy) between February and June, 2015. The dogs’ owners 
were informed about the purpose and design of the study and 
they provided a written informed consent before the enroll-
ment of their animal. All procedures, treatments and animal 
care were in compliance with the guidelines of the Italian Min-
ister of Health for the care and use of animals (D.L. 4 March 
2014 n. 26 and D.L. 27 January 1992 n.116). Inclusion criteria 
were: presence of clinical and radiographic signs of OA on at 
least one joint with no evidence of any other disease accord-
ing to the clinical history, physical examination and blood test 
results. Exclusion criteria were: dogs with acute pain, signs of 
recent trauma or surgery on any joint in the past 6 months, 
neurological conditions, treatment with NSAIDs, corticoster-
oids or antimicrobials within 14 days before enrolment.
Study design and the dietary supplement 
 This study was designed as a prospective observation-
al clinical study. Tablets of a dietary supplement produced by 
the Candioli Pharma S.p.A (Italy) containing mainly Boswellia 
serrata Roxb., Curcuma longa and green tea extract in addition 
to glucosamine (purity 99%), chondroitin sulfate (low molecu-
lar weight, purity 100%), hyaluronic acid, collagen type II-not 
hydrolised, were orally administered in dogs once daily for a 
total of 60 days. A full list of ingredients is reported in Table 1. 
The dose was calculated according to animals’ weight. All dogs 
were subject to a veterinary evaluation and an owner evaluation 
at different time points during the observational period: base-
line (T0), then after 30 (T1) and 60 (T2) days. All applicable 
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international, national and/or institutional guidelines for the 
care and use of animals were followed.
Ingredients Quantity in 2.0 gr of 
tablet (mg)
Hyaluronic acid 18
Appetite stimulants (D'Tech 8P) 134
Collagen type II-not hydrolised 4
Chondroitin sulfate 300
FLEXIDE® (Camellia sinensis (L.) O. 
Kuntze, Boswellia serrata Roxb. ex 
Colebr., Copper complexes of chlo-
rophylls E141)
70
Glucosamine hydrochloride 500
Technological additives (antioxi-
dants, emulsifiers, stabilizing agents)
974
 
Table 1. Ingredients included in the tested supplement. Quan-
tity of each ingredient contained in 2.0 grams of tablet is re-
ported. 
Veterinary Evaluation
 An orthopedic veterinary specialist performed the 
medical assessment of each dog at baseline, at 30 and at 60 
days post-treatment. During the visits, clinical general exami-
nation, orthopedic examination, blood test (complete blood 
count and blood chemistries, at T0 and T2 only) were per-
formed. A radiological assessment was carried out at the first 
visit to confirm the diagnosis, no significant changes in the 
radiographic findings are expected to be found after 60 days 
of treatment, indeed no other x-ray were performed at T1 and 
T2. Data on sex, age, breed, body weight, body condition score 
(BCS, 9 points scoring system), body temperature, examina-
tion of superficial lymph nodes, heart/pulse rate, respiratory 
character, and mucous membrane color were recorded. In ad-
dition, the specialist evaluated the animal pain progression 
grading the lameness at T0, T1 and T2 (1 to 4 scale, where 1 is 
for mild and 4 is for severe). Based on the classification of the 
type of lameness, the change in condition from T0 to T2 was 
also recorded. Indeed, the animals were classified at the end 
of the study as “successful” (no longer lame), “improved” (im-
provement from T0 to T2 with reduction of clinical signs and 
pain; i.e. from continuous to intermittent lameness), “failure” 
(unchanged clinical condition or worsened).
Owner Evaluation
 Chronic pain was assessed with an Italian adapted 
version of the validated Helsinki Chronic Pain Index (HCPI), a 
functional behavior-based owner questionnaire for veterinar-
ian use based on an article written by Canapp and colleagues 
[7] (Table 2). Questions translated from English into Italian 
might be slightly different due to wording and language varia-
tions, despite this the validity of the Index is not compromised. 
The questionnaire contains 11 questions on the dog’s mood, 
lameness, and willingness to move, play, and jump. The ques-
tionnaire takes into account the emotional aspect of the pain. 
The index number was derived from the 5 possible answers 
(scores of 0-4, scores of 0 and 1 indicate normal behavior and 
movement, scores of 2, 3, and 4 indicate pain with increasing 
severity). Owners were asked to mark only the answer that best 
described their dog. There is a possible minimum index num-
ber of 0 (11 x 0) and a possible maximum index number of 44 
(11 x 4). Therefore, healthy dogs usually have an HCPI between 
0 and 11, assuming that an individual score of 1 is considered 
normal. Dogs with chronic pain will have a score of 12–44. 
This index is one of the most commonly applied as an outcome 
measure in clinical trials where chronic pain is evaluated by 
owners [4-6]. 
Statistical Analysis
 Mean dog weight (Kilograms, Kg), age (years, yr) and 
standard deviation (SD) were calculated. Fraction of males and 
females were reported. Median value of the starting point of 
the lameness expressed in months was calculated. Percentage 
of animals with different grades and type of lameness and the 
fraction of animals classified as improved, failure or successful 
were included in the results. Graphical representations (histo-
grams) of the HCPI questionnaire outcomes were performed.
Results
 All the 13 patients enrolled in the study completed 
the protocol. Dogs’ ages ranged from 18 months to 10 years 
(mean 4.8 ±2.8 SD), with 4 dogs (31%) being females and 9 
dogs (69%) being male. Breeds of dogs in the study were: Ger-
man Shepherds (3), Setter (3), Siberian Husky (1), Dobermann 
(1), Pitbull terrier (2), Mixed Breed (2), one was not reported. 
They were all companion dogs. Body weights ranged from 15 
to 36 kg (mean 27.7 ± 8.1 SD kg). The two eldest dogs had a 
BCS of 7/9 and 8/9. The other dogs had a BCS of 3/9 (4 dogs) 
and 5/9 (6 dogs), one score was missing. The superficial lymph 
nodes, heart/pulse rate, respiratory character, the rectal body 
temperature and mucous membrane color were confirmed as 
normal in all animals during the three examinations. Differ-
ences in blood test results at the beginning and at the end of the 
study were negligible and closely linked to the individual ani-
mal pre-existing conditions, no significant changes in the renal 
and liver function was reported. The radiographic examination 
confirmed OA condition in all cases with one or more joints 
involved. More specifically, the joints affected by OA (number 
of cases) are listed here: knee (3 unilateral), knee and elbow 
(1 bilateral), hip (2 unilateral), tarsus (1 unilateral, 1 bilateral), 
carpus and shoulder (1 unilateral), carpus and elbow (1 unilat-
eral), carpus (1 bilateral), elbow (1 unilateral, 1 bilateral). 
 No side effects of the supplement were reported; no 
episodes of diarrhea or vomiting was pointed out. Moreover, 
none of the owners had difficulties in the administration of the 
tablets.
 
 The owners informed the veterinarian about the start-
ing point of the lameness in their dogs, it ranged approximately 
between 2-24 months (median=6) before the enrollment in the 
study. 
 The specialist evaluated the animal lameness progres-
sion grading it at T0, T1 and T2 during the performed ortho-
pedic examinations (Table 3). Specifically, four animals started 
with grade 2 (4/13, 31%), six animals with grade 3 (6/13, 46%), 
and three with grade 4 (3/13, 23%). In only two cases the grade 
of lameness remained the same, in the other cases an improve-
ment was recorded as showed in Table 3.
 In addition, the veterinarian evaluated the change in 
the type of lameness through the whole study period (Table 3). 
Most of the animals started with a continuous lameness at the 
first visit (8/13, 62%), while four with continuous cold lame-
ness (4/13, 31%) and one with intermittent lameness (1/13, 
8%). As regards the type of lameness, after the 60 days of treat-
ment most of the animals meliorate their clinical condition 
(9/13, 69%), and four animals remained the same (4/13, 31%).
Finally, the animals were classified at the end of the study 
based on the whole set of clinical examinations as “successful” 
(1/13, 8%), “improved” (11/13, 84%) or “failure” (1/13, 8%) 
(Table 3).
 Questionnaires were completed by all the owners at 
T0, T1 and T2. Only two questionnaires, one at T0 and one 
at T1, had been excluded from part of the analysis since we 
had missing answers and the total Index couldn’t be calcu-
lated. Based on the HCPI, in only three cases (3/11, 27%) we 
had a baseline Index slightly lower than 11, corresponding to 
the upper limit for considering a dog “healthy” based on the 
literature. The other Indexes varied from 11 to 33 (Figure 1). 
Dogs with a HCPI between 11 and 19 at T0 had a final score at 
T2 similar to the initial one, no significant differences can be 
highlighted (Figure 1). The three cases with the highest Index 
(HCPI >20), representing the set of animals with the maxi-
mum intensity of chronic pain in our study based on owners’ 
evaluation, showed a final score reduced significantly after the 
60 days of treatment (Figure 2). No age, weight, breed or sex 
effect was observed (data not shown) on the outcomes of in-
terest but the study was not designed for this purpose and the 
number of cases were not enough to perform further statistical 
analysis.
Discussion
 
 OA is frequently encountered in veterinary practice 
and is associated with important changes in animal behavior 
and activities. The main focus of the clinician is managing 
pain in affected animals and slowing down the progression of 
disease and improving exercise tolerance, mobility, and quality 
of life. Currently, several therapeutic options are available to 
Question asked 0 Points 1 Point 2 Points 3 Points 4 Points
Q1
Rate your dog’s mood
Very alert Alert Neither alert 
nor indifferent
Indifferent Very indifferent
Q2
Rate your dog’s willingness to partici-
pate in play
Very willing Willing Reluctantly Very reluctantly Does not play 
at all
Q3
Rate your dog’s vocalization (audible 
complaining)
Never Hardly ever Sometimes Often Very often
Q4
Rate your dog’s willingness to walk
Very willing Willing Reluctantly Very reluctantly Does not walk 
at all
Q5
Rate your dog’s willingness to trot
Very willing Willing Reluctantly Very reluctantly Does not trot 
at all
Q6
Rate your dog’s willingness to gallop
Very willing Willing Reluctantly Very reluctantly Does not gallop 
at all
Q7
Rate your dog’s willingness to jump 
(e.g., into car, onto sofa)
Very willing Willing Reluctantly Very reluctantly Does not jump 
at all
Q8
Rate your dog’s ease in lying down
With great ease Easily Neither easily 
nor difficultly
With difficulty With great dif-
ficulty
Q9
Rate your dog’s ease in rising from a 
lying position
With great ease Easily Neither easily 
nor difficultly
With difficulty With great dif-
ficulty
Q10
Rate your dog’s ease of movement after 
long rest
With great ease Easily Neither easily 
nor difficultly
With difficulty Very often/al-
ways difficulty
Q11
Rate your dog’s ease of movement after 
major activity or heavy exercise
With great ease Easily Neither easily 
nor difficultly
With difficulty Very often/al-
ways difficulty
Table 2. Helsinki Chronic Pain Index (HCPI) for veterinary use, as translated from Finnish to English based on an article writ-
ten by Canapp and colleagues [7].
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Cases Degree of lameness Type of lameness Overall clas-
sificationT0 T1 T2 T0 T1 T2
Case 1 2 1 1 continuous 
lameness
cold lameness Intermittent 
lameness
Improved
Case 2 3 3 2 continuous 
lameness
continuous 
lameness
cold lameness Improved
Case 3 2 2 2 continuous 
lameness
continuous 
cold lameness
intermittent 
cold lameness
Improved
Case 4 2 1 2 continuous 
lameness
cold lameness cold lameness Improved
Case 5 3 1 1 continuous 
cold lameness
no lameness no lameness Success
Case 6 3 2 2 continuous 
lameness
continuous 
cold lameness
continuous 
cold lameness
Improved
Case 7 3 2 1 continuous 
cold lameness
continuous 
cold lameness
intermittent 
lameness
Improved
Case 8 3 2 2 continuous 
lameness
continuous 
lameness
cold lameness Improved
Case 9 4 3 NA continuous 
cold lameness
continuous 
lameness
intermittent 
cold lameness
Improved
Case 10 2 2 1 Intermittent 
cold lameness
Intermittent 
cold lameness
Intermittent 
cold lameness
Improved
Case 11 4 4 4 continuous 
cold lameness
continuous 
lameness
continuous 
lameness
Failure
Case 12 3 2 2 continuous 
lameness
continuous 
lameness
continuous 
lameness
Improved
Case 13 4 2 2 continuous 
lameness
NA cold lameness Improved
Table 3. Patients’ lameness progression. Degree of lameness at T0, T1 and T2. Type of lameness at T0, T1 and T2. Overall clas-
sification of the animal’s condition after 60 days from the beginning of the treatment.
                  
                     
 
Figure 1. The Helsinki chronic pain index (HCPI) at T0 (tot_T0) and T2 (tot_T2) in 9 cases with baseline HCPI <20. On the top 
of each bar the HCPI is reported.
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the veterinarian and the use of oral supplements is becoming 
a popular option presenting the advantage of having few or no 
known side effects [22]. In agreement with the scientific litera-
ture, the supplement we administered in this study didn’t have 
an influence on the metabolic condition of the patients be-
ing the general clinical conditions and blood test results very 
similar to the baseline and no other side effects were reported. 
This clearly confirms the safety and tolerability of the admin-
istered product in our patients. Being OA a chronic disease, 
long-term treatments with products with minor side-effects 
are preferred. The risk of side-effects associated with long-
term administration of commonly used drugs like NSAIDs, 
has led to have increased interest in disease modifying agents 
such as diet supplements [8]. There is some evidence that a 
prolonged, regularly and conscientiously administered use of 
supplements (8 weeks or longer) is required to see significant 
improvements in patients [15]. Indeed, we planned a 60 days 
study period and at the end of the study, we were able to see 
good improvements in clinical signs and behavior. It is very 
common in the veterinary practice to see a beneficial effect 
of a treatment with either traditional drugs or supplements 
when the lameness and pain are severe. In fact, during our 
study we found three cases we classified as the most severe 
and both the veterinarian and the owner pointed out an evi-
dent positive outcome after the 60 days of treatment. In one 
case we even reported the actual success. In the other dogs (a 
part from one) an improvement of the clinical conditions was 
highlighted by the specialist only and this can be considered 
a very good result for the treatment of less severe cases. On 
the other hand, based on the HCPI, we cannot confirm that 
in these same cases the animal mood, lameness, and willing-
ness to move, play, and jump based on the owner’s opinion 
were ameliorated. The reason why this happened could be ad-
dressed to the less serious general condition of the dog and the 
smaller pain reported at the baseline compared to the most 
severe cases. Chronic pain is very difficult to assess, and even 
if psychometric properties of the questionnaire used are valid 
                     
Figure 2. The Helsinki chronic pain index (HCPI) at T0 (tot_T0) and T2 (tot_T2) in the three cases with baseline HCPI 
>20. On the top of each bar the HCPI is reported.
and reliable, the capability of the owner to see differences in 
their animal behavior in this conditions is minimal. Unfor-
tunately, pain status for some dogs might change even from 
day to day, depending on weather, extra activity, and other 
events, making any interval between the two visits too long 
to get the score the closest to the reality [5]. Answering to the 
questionnaire could be quite subjective, and a difference of a 
few points could have varied our final HCPI. Finally, in these 
less severe cases we could consider the specialist final report 
the most reliable result of the treatment. In general, diet sup-
plements have been reported to be well tolerated and absorbed 
quickly, but some authors pointed out that further studies are 
needed to add information concerning their bioavailability, 
the mechanism of action of some products is often speculative 
and their efficacy not always supported by rigorous scientific 
studies [22]. Despite this, using diet supplements and in par-
ticular, multicomponent formulations seems to be very com-
mon in the recent research and in practice, with the idea that 
several components together have an optimal effect [23]. Fol-
lowing this, the novelty of our diet supplement is the mixture 
of several ingredients each of them reported in literature to 
have relevant positive effects (used singly or in combination) 
on the treatment of different inflammations and in particular 
on OA in humans and animals. But, in none of these studies 
they were all combined together as it is in our formulation. For 
example, some studies have indicated that when administered 
together to dogs, glucosamine and chondroitin are absorbed 
in as little as two hours [16] and the action is even synergistic 
[24], moreover the addition of undenatured Type II Collagen 
was found even more effective in a placebo-controlled study 
conducted by D’Altilio and colleagues [17]. In another study 
performed with working dogs, similar effects were noticed in 
the group treated with a diet supplement (glucosamine, chon-
droitin sulphate, and hyaluronic acid) and in the one with 
Carprofen [15]. As regards natural curcumin we used in our 
supplement, a major concern in the literature is the absence 
of information concerning its bioavailability in dogs. In fact, 
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it is known for its very low bioavailability as also reported in 
Comblain and colleagues [22]. But, the technology used for 
the formulation of both Boswellia serrata Roxb. and Curcuma 
longa as phytosomes in our supplement, was really patented in 
order to ensure the better intestinal absorption. In a study con-
ducted by Reichling and colleagues [13], these two important 
ingredients were found to be effective in the treatment of dogs 
suffering from inflammatory joint and spinal disease. This is 
evidence in support of our choice of including also these two 
natural ingredients in our preparation. Finally, curcuminoids 
extract, in combination with hydrolyzed collagen and green 
tea extract, was also found to be effective in an in vitro study 
[21]. 
Conclusion
 Our results indicated that the dietary supplement 
was beneficial in alleviating chronic orthopedic pain and in 
reducing the clinical signs in dogs with OA after 60 days of 
treatment. This study supports the concept that oral supple-
ments with a combination of natural products can be effec-
tively used in managing the natural OA process in dogs with 
no or negligible side effects. Based on the limited number of 
cases and the absence of a control group, further studies would 
be useful to consolidate our results.
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